11 completed, 7 withdrawn, 6 recruiting, 4 active not recruiting. 13 Not applicable, 7 Phase 1, 7 Phase 2, 2 Early Phase 1.
Follow Magnetic Resonance Spectroscopic Imaging: new trials by email Literature Review of Magnetic Resonance Spectroscopic Imaging trials Research Report on Magnetic Resonance Spectroscopic Imaging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection - Malignant Central Nervous System Neoplasm | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-20 | 2025-10-22 | |
| MRSI Evaluation for Minor Stroke With Large Vessel Occlusion Magnetic resonance spectroscopic imaging - Acute Ischemic Stroke | Recruiting | Shanghai 6th People's Hospital | 75 | 2024-08-15 | 2024-10-16 | |
| Assessing Neuroinflammation in GWI Using MRS Magnetic Resonance Spectroscopic Imaging, Blood draw - Gulf War Syndrome | Completed | University of Alabama at Birmingham | 49 | 2020-12-01 | 2025-01-13 | |
| Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, Surgical Procedure - Prostate Adenocarcinoma | Withdrawn | M.D. Anderson Cancer Center | 2019-12-19 | 2026-09-15 | ||
| Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging - Primary Brain Neoplasm | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 13 | 2019-05-16 | 2026-07-16 |
| Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging - Prostate Adenocarcinoma, PSA Level Greater Than Ten | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-02-06 | 2025-04-23 | |
| Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors Magnetic Resonance Spectroscopic Imaging, Proton Therapy - Malignant Brain Glioma | Not applicable | Recruiting | Emory University | 25 | 2018-12-20 | 2026-03-04 |
| Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging - Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 | Completed | Daniel M. Spielman | 9 | 2018-11-06 | 2023-12-21 |
| Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Recruiting | University of California, San Francisco | 60 | 2018-07-18 | 2026-05-18 |
| Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma Dose-Escalated Radiation Therapy, Spectroscopic Magnetic Resonance Imaging, Temozolomide - Glioblastoma, Gliosarcoma | Phase 2 | Completed | Emory University | 30 | 2017-09-20 | 2025-08-03 |
| MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer Diffusion Weighted Imaging, Magnetic Resonance Spectroscopic Imaging - Benign Breast Neoplasm, Breast Carcinoma | Early Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 83 | 2017-07-31 | 2024-04-17 |
| Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging - Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma | Phase 1 | Recruiting | Susan Chang | 300 | 2017-01-11 | 2026-04-29 |
| Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer Hyperpolarized 13C-Pyruvate, Hyperpolarized 13C,15N2-urea, Magnetic Resonance Spectroscopic Imaging - Prostate Cancer, Localized Prostate Carcinoma | Early Phase 1 | Recruiting | Ivan de Kouchkovsky, MD | 80 | 2016-03-22 | 2026-04-30 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells - Recurrent Glioblastoma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | City of Hope Medical Center | 65 | 2015-05-18 | 2026-07-28 |
| MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer Computed Tomography, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Terminated | University of Washington | 51 | 2014-02-14 | 2023-06-26 | |
| Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer high field strength magnetic resonance imaging, magnetic resonance spectroscopic imaging, chemical exchange saturation transfer magnetic resonance imaging - Breast Cancer | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2013-01-01 | 2016-08-03 |
| New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Not applicable | Completed | M.D. Anderson Cancer Center | 273 | 2012-04-16 | 2022-10-28 |
| Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma vorinostat, temozolomide, magnetic resonance spectroscopic imaging - Adult Glioblastoma, Depression | Not applicable | Completed | National Cancer Institute (NCI) | 12 | 2010-12-01 | 2018-01-29 |
| MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy blood-oxygen-level-dependent functional magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging - Prostate Cancer | Not applicable | Withdrawn | University of Texas Southwestern Medical Center | 2009-09-01 | 2018-11-26 |
Showing 20 of 34. Sign in to see all of them.
Prostatic Neoplasms (8) · Breast Neoplasms (6) · Central Nervous System Neoplasms (6) · Glioma (6) · Glioblastoma (5) · Brain Neoplasms (4) · Astrocytoma (3) · Ependymoma (3) · Gliosarcoma (3) · Glioma, Subependymal (2) · Oligodendroglioma (2) · Carcinoma, Ductal, Breast (1) · Clinical Deterioration (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Depression (1)
M.D. Anderson Cancer Center (4) · Jonsson Comprehensive Cancer Center (3) · Emory University (2) · National Cancer Institute (NCI) (2) · University of California, San Francisco (2) · Vanderbilt-Ingram Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · American College of Radiology Imaging Network (1) · Cancer Clinical Trials Unit, Scotland (1) · Cancer Research UK (1) · Children's Cancer and Leukaemia Group (1) · City of Hope Medical Center (1) · Daniel M. Spielman (1) · Ivan de Kouchkovsky, MD (1) · Mayo Clinic (1)
United States (24) · United Kingdom (4) · Canada (2) · China (1) · Hong Kong (1)
Ivan de Kouchkovsky, MD (2) · Jeffry Alger, PhD (2) · A. Bapsi Chakravarthy, MD (1) · Anna Kirby (1) · Anurag K. Singh, MD (1) · Behnam Badie (1) · Bree R Eaton, MD (1) · Dawid Schellingerhout (1) · Douglas Yee, MD (1) · Eugene I Hwang (1) · Hui-Kuo Shu, MD, PhD (1) · Jarred Younger, PhD (1) · Jeffrey Olson (1) · Jeffrey Weinreb, MD (1) · John Madewell (1)
PMID 17222711, PMID 23157877, PMID 25055291, PMID 28029927, PMID 30854456, PMID 32548285, PMID 37218946, PMID 37707401, PMID 38454126, PMID 41137912
R01CA211150 (3), P30CA138292 (2), R01CA300053 (2), R01EB017449 (2), P30CA033572 (1), P30CA068485 (1), P30CA077598 (1), P50CA097257 (1), R01CA155454 (1), R01CA214554 (1), R01CA214557 (1), R01CA238379 (1), R01CA245097 (1), R01CA262630 (1), R21CA141836 (1)